From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - 3SBio Inc.'s success with a biosimilar of Amgen Inc.'s erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government
You may also be interested in...
3SBio Discontinues NuLeusin; Sinovac To Benefit From Government Vaccine Supply Plan: China Earnings Roundup (Part 3)
China's generic pharma companies suffered a slowdown in Q3, but biotech companies saw healthy growth.
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services